Biography
Dr. Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is a Professor of Pathology at Harvard Medical School. He is the Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology, and is an Institute Member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. He has published over 400 papers in prominent journals describing new methodologies to study cancer genomes that have identified new genes and pathways involved in different tumor types, mutational signatures, and tumor evolution.

Biography
Stephen Quake is the Lee Otterson Professor of Bioengineering and Applied Physics at Stanford University. He has received numerous awards for his contributions to science and is one of only two dozen scientists elected to all three National Academies. Previously he was the Head of Science at Chan Zuckerberg Initiative (2022-2025), founding co-president of the Chan Zuckerberg Biohub (2016-2022), Investigator of the Howard Hughes Medical Institute (2006-2016), and Professor at the California Institute of Technology (1996-2005).

Biography
Dr. Michael Kahana is CEO and co-founder of Nia Therapeutics, which is developing an AI-guided closed-loop neurostimulation therapy for memory loss. During his 30-year academic career, Kahana published more than 200 scientific articles and won numerous awards for his pioneering research on the neural basis of human memory and for his contributions ot memory theory.

Biography
Ari is Cofounder and CSO at Weave Bio. Weaves native-AI regulatory platform helps life science companies to weave together data and documentation for all regulatory submissions, from pre-IND to NDABLA, directly from the source data and studies.Previously, Ari was the first Chief Analytics Officer at Memorial Sloan Kettering Cancer Center (MSK) where he drove pioneering efforts using clinical data to analyze patient outcomes. Aris team at MSK developed the first operational AI model to match patients to clinical trials. While at MSK, Ari also contributed to the creation of startups like Flatiron Health and Paige AI. In 2019, Ari cofounded Daat.AI which was acquired by Tempus AI, where Ari served as SVP of RWD.

Biography
Dr. Nath is a cancer biologist with expertise in both experimental and computational biology. At City of Hope, Dr. Nath leads a collaborative research team that investigates the potential of AIML in enhancing cancer patient outcomes. Through the integration of bioinformatics and AIML tools, his research aims to unravel the underlying mechanisms of tumor progression and establish cutting-edge biomarkers for improving the clinical outcomes of patients with cancer. His research employs multi-omics approaches to identify the drivers of tumor evolution and the subsequent development of drug resistance. Dr. Nath aspires to translate research findings into clinical impact, notably contributing to upcoming clinical trials in lung and breast cancer that will implement novel AI-guided biomarkers. Dr. Nath currently is a principal investigator (PI) of an ARPA-H grant, an NIH U01 grant, a PHASE ONE foundation grant, a JKTG foundation grant, and co-investigator of an ARPA-H and California Institute for Regenerative Medicine (CIRM) grant.

Biography
Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of KhoslaVentures, focused on impactful technology investments in software, AI, robotics, 3Dprinting, healthcare and more. Mr. Khosla was a co-founder of Daisy systems and foundingCEO of Sun Microsystems where he pioneered open systems and commercial RISCprocessors. One of Mr. Khoslas greatest passions is being a mentor to entrepreneurs,assisting entrepreneurs and helping them build technology-basedbusinesses. Mr. Khosla isdriven by the desire to make a positive impact through technology to reinvent societalinfrastructure and multiply resources. He is also passionate about Social Entrepreneurship.Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, aMaster's in Biomedical Engineering from Carnegie Mellon University and an MBA from theStanford Graduate School of Business.

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and AIML.

Biography
Greg Brockman is the President and Co-Founder of OpenAI, where he currently leads the companys Scaling organizationfocused on expanding the technical infrastructure and systems needed to support OpenAIs rapid growth and increasingly capable models. He has played a central role in shaping OpenAIs mission and in bringing transformative technologies like ChatGPT, DALLE, and Codex to millions of people and businesses around the world.Before OpenAI, Greg was the CTO of Stripe, where he built and led the engineering team during a period of rapid scale. He studied mathematics at Harvard and computer science at MIT before leaving to pursue a career at the forefront of technology.Greg is a technologist and builder, deeply invested in ensuring artificial general intelligence is developed safely and benefits all of humanity. He regularly speaks on the future of AI, responsible deployment, and the infrastructure powering the next generation of intelligent tools.

Talk
Fireside Chat

Biography
Massa Shoura is the CEO and CSO of Phinomics, an innovative company transforming precision medicine by unlocking the potential of circular DNA and integrating genomics with advanced AI. With dual PhDs in Molecular Biology and Biomedical Engineering, Massa has over a decade of expertise in DNA topology, biophysics, and genomics. During her postdoctoral fellowship at Stanford University in Nobel Laureate Dr. Andrew Fires lab, she developed groundbreaking tools for isolating and characterizing circular DNA, earning prestigious fellowships, including the Arnold O. Beckman Fellowship, and securing two granted patents. As a Forbeck Scholar, she advanced cancer genomics by uncovering the role of oncogenic circular DNA amplification. She also spearheaded the sequencing and publication of Pfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment to global health. At Phinomics, Massa leads the development of first-in-class precision oncology solutions through the Circulome Atlas, a transformative platform providing unparalleled insights into cancer etiology, progression, and therapeutic resistance.

Biography
Rajat Roy is a serial entrepreneur and technology leader serving as CEO Co-founder of PathomIQ Inc. pathomiq.com With expertise spanning enterprise AIML, diagnostics, and health tech, he has led two prior successful startup exits. pathomiq.comUnder his leadership, PathomIQ has advanced its AI-powered diagnostic platform (PathomIQ_PRAD) for prostate cancer in collaboration with Myriad Genetics. myriad.gcs-web.com+1 The platform applies machine learning to analyze digital pathology images, supporting predictions of patient outcomes, treatment response, and genotypic features in 12 days. Haynes Boone+1Rajat holds educational credentials from Stanford University, and is based in the San Francisco Bay Area.

Biography
Omar has decades of experience designing global cloud platforms pioneering the use of collaborative feedback networks to solve challenging information extraction problems. He is the Principal Architect of precisionFDA.gov, the FDA cloud platform that is transforming the regulatory research and review process for precision drugs and devices. Prior to DNAnexus, Omar managed operations for the AWS Elastic Compute Cloud when single regions were topping the one-million server mark. Previously, he led platforms for a Twitter search engine at Topsy Labs, and crowd-sourced messaging security at Cloudmark. Omar received his Bachelor of Science in Chemistry from UC Berkeley.

Biography
Greg Brockman is the President and Co-Founder of OpenAI, where he currently leads the company’s Scaling organization—focused on expanding the technical infrastructure and systems needed to support OpenAI’s rapid growth and increasingly capable models. He has played a central role in shaping OpenAI’s mission and in bringing transformative technologies like ChatGPT, DALL·E, and Codex to millions of people and businesses around the world. Before OpenAI, Greg was the CTO of Stripe, where he built and led the engineering team during a period of rapid scale. He studied mathematics at Harvard and computer science at MIT before leaving to pursue a career at the forefront of technology. Greg is a technologist and builder, deeply invested in ensuring artificial general intelligence is developed safely and benefits all of humanity. He regularly speaks on the future of AI, responsible deployment, and the infrastructure powering the next generation of intelligent tools.

Biography
Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of KhoslaVentures, focused on impactful technology investments in software, AI, robotics, 3Dprinting, healthcare and more. Mr. Khosla was a co-founder of Daisy systems and foundingCEO of Sun Microsystems where he pioneered open systems and commercial RISCprocessors. One of Mr. Khoslas greatest passions is being a mentor to entrepreneurs,assisting entrepreneurs and helping them build technology-basedbusinesses. Mr. Khosla isdriven by the desire to make a positive impact through technology to reinvent societalinfrastructure and multiply resources. He is also passionate about Social Entrepreneurship.Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, aMaster's in Biomedical Engineering from Carnegie Mellon University and an MBA from theStanford Graduate School of Business.

Biography
A Silicon Valley icon, technology entrepreneur, and philanthropist for more than four decades, Steve Wozniak has helped shape the computing industry through his design of Apples first line of products the Apple I and II and his influence on the Macintosh. In 1976, Wozniak and Steve Jobs co-founded Apple Computer Inc. with Wozniaks Apple I, followed by the Apple II, which helped launch the personal computer revolution. He is listed as the sole inventor on four Apple patents.After completing his degree in electrical engineering and computer science at UC Berkeley, Wozniak founded Unuson, producer of the US Festivals a landmark fusion of technology and music. His achievements have been recognized with the National Medal of Technology from President Ronald Reagan, induction into the National Inventors Hall of Fame, and the Heinz Award for Technology, the Economy and Employment.A committed advocate for education and innovation, Wozniak has championed technology access in schools and supported institutions such as the Electronic Frontier Foundation, the Tech Museum of Innovation, and the Childrens Discovery Museum of San Jose. He is the author of the New York Times best-selling autobiography iWoz and continues to advance technology education as co-founder of Woz U and Efforce, a blockchain-based sustainability platform.

Biography
Dr. Musso has a background in molecular genetics (PhD), and did post-doctoral work at Harvard Medical School and Brigham and Women's Hospital on computational and developmental biology. He spent time at a start-up working on real-time machine learning, before joining with others to start BioSymetrics with the aim of tackling the specific challenges of working with biomedical data. He was named one of the top 100 leaders in AI and drug discovery, has authored over 30 peer reviewed publications on AIML and biology.

Talk
Closing the loop: Coupling AI with In vivo validation
AI models are accelerating target and compound discovery, but translation remains a bottleneck. We present a closed-loop platform integrating predictive AI with high-throughput in vivo validation using disease models relevant to neurological disease. Case studies demonstrate how this approach improves hit prioritization, enhances biological relevance, and increases success rates in drug development.

Biography
Dr. Georgescu spearheads Vivodyne's vision of reshaping therapeutics development. The loss of translation between animal studies and human trials compelled him to co-found Vivodyne in 2020 and create an entirely new platform from the ground up. With a Ph.D. from Dr. Huh's esteemed organ-chip research group at the University of Pennsylvania, his expertise lies in human-tissue engineering, robotics, and machine learning. His prior achievements include sending lab-grown tissues with NASA to space and developing DNA synthesis chips that remain industry staples to this day.

Biography
Harlan Robins is a CoFounder of Adaptive Biotechnologies, a commercial stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to cofoundingconfounding Adaptive, Harlan served in various roles at the Fred Hutchinson Cancer Research Center (FHCRC) in the Computational Biology Program, including Assistant Faculty Member, Associate, and Full Member and Head of the program. Interested in the mathematics behind genetics and observing the potential utility of high level mathematics to study problems in the biological sciences, Harlan took a postdoctoral appointment at the Institute for Advance Study in Princeton under famed biologist Dr. Arnold Levine. With Dr. Levine, he concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his faculty appointment at FHCRC in the Computational Biology Group, Public Health Sciences and Human Biology Divisions.

Biography
Vitalay Fomin, Ph.D.,CEO of Numenos AI, is an award-winning data scientist at RocheGenentech specializing in biomarker and reverse translation drug discovery

Talk
CURE AI provides efficacy signal from single arm trials
We developed a novel foundation model that is biologically aware capable of using single arm trials to identify optimal indication, patient population and drug combination and optimizes each asset for maximal clinical trial success

Biography
Dr. Amar Das has three decades of experience in advancing clinical research through data science and AI. At Guardant Health, he leads a team that generates real world evidence for blood-based testing in precision oncology and cancer screening. Prior to Guardant Health, Dr. Das was on the faculty at Stanford and Dartmouth. As Director of Biomedical Informatics at Dartmouth, he co-founded the Department of Biomedical Data Science, the first department focused on this discipline. Following his career in academia, he served as Director of Healthcare Effectiveness Research at IBM and Director of Real World Data Analytics and Innovation at MerckMSD. Dr. Das has received multiple professional and research awards, and is a Fellow of the American College of Medical Informatics. Dr. Das received his MD and PhD in Biomedical Informatics from Stanford and completed his residency and postdoctoral fellowship in Clinical Epidemiology at ColumbiaNew York Presbyterian.

Biography
Watsons current work focuses on AI-driven biomolecular design, creating predictive peptides and receptor-targeting ligands that are engineered to precisely deliver nanoparticles, gene-editing tools, drugs, and nucleic acids to specific cells and tissues. This approach aims to enhance therapeutic specificity, reduce toxicity, and accelerate the development of curative and preventative delivery of therapeutics. Previously, while researching at Rensselaer Polytechnic Institute, he developed gene-editing delivery platforms for guided nucleases like CRISPR and TALEN. Today, he applies AI and predictive physics to rapidly generate and evaluate novel targeting agents, mapping uncharted receptor-ligand relationships as an enabling technology for biopharmaceutical delivery systems. With over 80 pending global patents (22 approved, 6 allowed), Watsons work pioneered integrating cell surface transcriptomics, predictive targeting ligand design, and drug and gene delivery systems. He and his team aim to transform how we approach the worlds most challenging diseases, advancing the frontier of precision therapeutics and diagnostically-responsive medicine.

Biography
Colin Hill is a trailblazer in applying causal AI to precision medicine. Aitia, the company he co-founded and leads, has built a powerful Digital Twin discovery and drug development platform, with a current focus on neurodegenerative diseases and oncology. He serves on the boards of Fulcrum Therapeutics (NASDAQ: FULC, a rare genetic disease company, Centrexion Therapeutics, a non-opioid pain therapeutics company, and the Critical Path Institute, which fosters collaborations between scientific and regulatory bodies.He previously served on the boards of mobile health company Biotelemetry Inc., CRO PPD Inc., and sickle cell disease company AesRx.In 2004, Colin was named to MIT Technology Reviews TR100 list of the top 100 innovators in the world under the age of 35. He has appeared in publications and television programs including The Wall Street Journal, CNBC Morning Call SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.

Talk
Gemini Digital Twins Accelerate Precision Medicine
The biggest obstacle to realization of precision medicine is poor knowledge of the complex biological circuitry underlying human health and disease. The convergence of raw computational power, multiomic and clinical data, and causal AI has led to Gemini Digital Twins, in silico circuitry models of virtually any disease (we will discuss Huntington's and prostate cancer).

Biography
Eric Horvitz, MD, PhD, is Chief Scientific Officer at Microsoft where he leads initiatives at the intersection of science, technology, and society, with emphases on artificial intelligence, biosciences, and healthcare. His research contributions have advanced AI through innovations in perception, reasoning, and decision-making under uncertainty.Dr. Horvitz is known for his contributions to AI theory and practice, with a focus on principles and applications of AI amidst the complexities of the open world. His direction-setting research efforts include harnessing probability and utility in machine learning and reasoning, developing models of bounded rationality, constructing systems that perceive and act via interpreting multisensory streams of information, and pioneering principles and mechanisms for supporting human-AI collaboration and complementarity. His efforts and collaborations have led to fielded systems in healthcare, transportation, ecommerce, operating systems, and aerospace.Beyond his scientific work, he has pursued programs, organizations, and studies on ethics, values, and safety with applications and influences of AI. He founded and chairs Microsofts Aether committee on AI, effects, and ethics in engineering and research. He established the One Hundred Year Study on AI(opens in new tab) at Stanford University and co-founded and served as board chair of the Partnership on AI(opens in new tab) (PAI). He served as a Congressionally appointed commissioner on the National Security Commission on AI(opens in new tab), where he chaired the line of effort on ethical and trustworthy AI.Dr. Horvitz received the Feigenbaum Prize and the Allen Newell Prize for his fundamental contributions to the science and practice of AI. He received the CHI Academy honor for his work at the intersection of AI and human-computer interaction. He has been elected fellow of the National Academy of Engineering(opens in new tab) (NAE), the Association of Computing Machinery (opens in new tab)(ACM), Association for the Advancement of Artificial Intelligence(opens in new tab) (AAAI), the American Association for the Advancement of Science(opens in new tab) (AAAS), the American Academy of Arts and Sciences(opens in new tab), the American College of Medical Informatics(opens in new tab), and the American Philosophical Society(opens in new tab).Dr. Horvitz currently serves on the advisory boards of the Allen Institute for AI (opens in new tab)(Ai2) and Stanfords Institute for Human-Centered AI(opens in new tab) (HAI). He served as a member of the Presidents Council of Advisors on Science and Technology(opens in new tab) (PCAST), president of the AAAI, as a member of the Computer Science and Telecommunications Board(opens in new tab) (CSTB) and Computing Community Consortium(opens in new tab) (CCC), and on advisory committees for the National Science Foundation(opens in new tab) (NSF), National Institutes of Health(opens in new tab) (NIH), and Defense Advanced Research Projects Agency(opens in new tab) (DARPA).He received Ph.D. and M.D. degrees at Stanford University. Before moving into the role of Chief Scientific Officer, he served as director of Microsoft Research overseeing research labs in Redmond, Washington; Cambridge, Massachusetts; New York City, New York; Montreal, Canada; Cambridge, United Kingdom; and Bangalore, India. More information can be found on his home page(opens in new tab). A selected list of publications can be found here(opens in new tab).

Biography
Ron Alfa is a physician scientist at the forefront of leveraging technology to tackle unmet therapeutic needs in medicine. He is Co-Founder and CEO of NOETIK, a next generation precision oncology company using multimodal foundation models pre-trained on large-scale human tumor data to discover cancer therapeutics. Prior to founding Noetik, Ron was Senior Vice President, Head of Research and acting-CSO at Recursion, where he led the companys scientific organizations and portfolio strategy. At Recursion, he led portfolio and platform builds across rare disease, neuroscience, oncology, and immunology, and was responsible for advancing multiple therapeutic programs from discovery to clinical development. Ron holds an MD and PhD from Stanford University School of Medicine, where he completed his doctoral work in Neuroscience, and has a MA in History of Medicine from UCL.

Biography
Lisa Gurry is the Chief Business Officer at GeneDx, where she is leading the company through its next phase of growth advancing data and information services across biopharma, health systems, and other partners to accelerate the future of precision medicine. In this role, Lisa drives GeneDxs strategic business operations and partnership models, unlocking the full potential of GeneDx Infinity, the largest rare disease dataset. She also oversees the companys communications function and collaborates on market growth strategies. With deep expertise at the intersection of healthcare, technology, and data, Lisa has a proven track record of turning bold ideas into scaled businesses. She co-founded Truveta, serving as Chief Growth Officer, Chief Marketing Officer, and Chief Operating Officer. She built the growth engine that helped secure strategic partnerships with more than 100 organizations across life sciences, healthcare, public health, and academic research. Earlier in her career, Lisa spent more than two decades at Microsoft, leading global teams and driving global growth strategies, marketing, and communications for Windows, Office, and Xbox. Lisa has a BA in communications from University of Arkansas, where she ran cross country and track. Lisa also has a daughter with several rare diseases, which culminated in a 13-year diagnostic odyssey. She is passionate about helping patients and families receive answers to transform lives.

Biography
Dr. Shivaani Kummar is Margaret and Lester DeArmond Chair of Molecular Oncology, Division Chief of Hematology and Medical Oncology, co-Director of the Center of Experimental Therapeutics, and Deputy Director for Clinical and Translational Research, Knight Cancer Institute, Oregon Health Science University, Portland, Oregon, USA. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. She is a member of scientific planning committees of national and international professional organizations and has authored over 160 peer reviewed publications, 9 book chapters, and co-edited a book on Novel Designs of Early Phase Trials for Cancer Therapies. She is currently a member of the American Association for Cancer Research Exploratory INDPhase 0 Clinical Trials Task Force, and co-Chair of the Clinical Trials Committee, AACR Annual Meeting 2023-2024.

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and AIML.